Seiji Miyahara

Seiji Miyahara joined Taiho Ventures in 2016. He is mainly responsible for investment identification, due diligence, new company creation and open innovation for Taiho Pharmaceutical. Seiji currently serves as a board observer or a board member for several portfolio companies. Prior to joining Taiho Ventures, he worked for Taiho Pharmaceutical for 12 years as a chemistry project leader in oncology field, where he was involved in the development of first-in-class dUTPase/DPD dual inhibitor (TAS-114) and a wide range of oncology drug discovery programs. He received his PhD in life science from Hokkaido University in Japan.